Published by Coherent Market Insights
Posted on October 1, 2021
4 min readLast updated: February 1, 2026
The Stem Cell Assay Market is set for growth from 2021-2027, driven by chronic disease prevalence and advancements in stem cell therapy.
Stem cells are a new generation of specialized cells which are not like the rest of your body cells. A stem cell is an undifferentiated mass of tissue which has the amazing capacity to multiply indefinitely without dividing as other body cells do. It is further distinguished into different specialized cells like bone cells (osteocytes), skin cells (melanocytes), blood cells (leukocytes), nerves, and heart cells.
Request Sample Copy of This Report @
https://www.coherentmarketinsights.com/insight/request-sample/1632
Increasing prevalence of chronic diseases is expected to propel growth of the global stem cell assay market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Moreover, effectiveness of autologous hematopoietic stem cell transplant in treatment of various diseases is also expected to aid in growth of the market. For instance, in November 2020, the National MS Society stated that autologous hematopoietic stem cell transplant represents “a useful treatment option” for patients with relapsing multiple sclerosis who experience breakthrough disease activity despite disease-modifying therapy.
R&D in stem cell therapy is expected to offer lucrative growth opportunities for players in the global stem cell assay market. For instance, in March 2020, researchers from Dankook University and Catholic University, South Korea, reported investigation of the types and degrees of physical and psychological discomfort experienced by hematopoietic stem cell donors before, during, and after the donation process.
Moreover, ability of stem cell assays to predict developmental toxicity potential of nicotine-containing products is also expected to aid in growth of the market. For instance, in December 2020, the new study, “The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes,” published online in the journal Current Research in Toxicology, supported the utility of the devTOX quickPredict (devTOXqP) human induced pluripotent stem cell (iPS)-based assay from Stemina Biomarker Discovery (Stemina) as the first human-based in vitro assay to effectively predict risk to early embryonic development induced by chemical exposure, including that from nicotine-containing products.
Major Players in Stem Cell Assay Market
Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.
Ask for PDF sample copy of the Stem Cell Assay market report @
https://www.coherentmarketinsights.com/insight/request-pdf/1632
Why this is Important Report to you? It helps:
• To analyze and study the Global Stem Cell Assay Market capacity, production, value, consumption, status Focuses on the Key Stem Cell Assay manufacturers, to study the capacity, production, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To define, describe and forecast the market by type, application, and region.
• To analyze the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
• To identify significant trends and factors driving or inhibiting market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Stem Cell Assay Market.
• To strategically profile the key players and comprehensively analyze their growth strategies.
• It provides a forward-looking perspective on different factors driving or restraining Market growth.
• It provides a six-year forecast assessed on the basis of how the Market is predicted to grow.
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors.
• It helps in making informed business decisions by having complete insights and by making an in-depth analysis of Market segment
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1632
In conclusion, the Stem Cell Assay market report presents the descriptive analysis of the parent market supported elite players, present, past, and artistic movement information which is in a position to function as a profitable guide for all the Stem Cell Assay industry business competitors. Our expert research analyst’s team has been trained to supply in-depth marketing research reports from every individual sector which can be helpful to know the industry data within the most precise way.
Contact:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Stem Cell Assay Market Highly positive outlook over the forecast period 2021-2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies appeared first on Gatorledger.
The article discusses the growth prospects of the Stem Cell Assay Market from 2021 to 2027.
The increasing prevalence of chronic diseases and advancements in stem cell therapy drive market growth.
Major players include Merck & Co., Thermo Fisher Scientific, GE Healthcare, and Agilent Technologies.
Explore more articles in the Research Reports category
